This comparison to human insulin highlights the advantage of oral delivery of insulin analogues such as OI320 or OI338 with a more restricted distribution within the central/blood compartment in order to reduce the risk of hypoglycaemia that may occur with variations in oral absorption and at the same time would caution against the use of regular human insulin or rapid-acting insulin analogues for oral therapy. Here, INS is linked to Hypoglycemia.